AngioGenex is a biopharmaceutical company committed to the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. AngioGenex and its collaborators, including Robert Benezra, Ph.D., and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Id proteins have been shown to play a key role in mediating the pathogenesis of certain cancers and diseases of the eye. AngioGenex’s lead development candidate is AGX-A, a novel small molecule being investigated for the treatment of cholangiocarcinoma (a form of liver cancer) and age-related macular degeneration (AMD). AngioGenex is headquartered in New York, NY.
Company Details
- Employees
- 4
- Address
- 425 Madison Ave, New York,ny 10017,united States
- Phone
- (347) 468-6799
- in****@****nex.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- angiogenex.com
- Keywords
- SynsoryBio.
- HQ
- New York, NY
Angiogenex Inc Questions
Angiogenex Inc's helpline number is (347) 468-6799
Angiogenex Inc's website is angiogenex.com
Angiogenex Inc's LinkedIn profile is https://www.linkedin.com/company/angiogenex-inc
Angiogenex Inc has
4 employees.
View email and phone details for 4
employees at Angiogenex Inc.
Angiogenex Inc's industry is
Biotechnology Research
Angiogenex Inc's top competitors are
Promakhos Therapeutics,
Deliver Therapeutics, Inc.,
Antiquity,
Kenox Pharmaceuticals, Inc,
Sharp Therapeutics,
Allos Pharma,
Synsorybio,
Sfa Therapeutics,
Vellos,
C16 Biosciences.
Angiogenex Inc's support email address is info@angiogenex.com
Angiogenex Inc's categories are Biotechnology Research
